News

Avadel Pharmaceuticals Shares New Details on Proxy Statement

Avadel Pharmaceuticals Shares New Details on Proxy Statement

Avadel Pharmaceuticals Announces Definitive Proxy Statement

Avadel Pharmaceuticals plc (NASDAQ: AVDL), a significant biopharmaceutical company focused on innovative medication solutions, has recently released key information regarding its ongoing acquisition process with Alkermes plc. This announcement marks an important step as the company pivots towards streamlining its governance and enhancing shareholder engagement.

Understanding the Proposed Transaction

The deal entails Alkermes acquiring the entire issued ordinary share capital of Avadel. This proposal, previously introduced under the Irish Takeover Rules, emphasizes the strategic intention to enhance operational efficiencies and broaden market reach. With a firm belief in the potential benefits, the boards of both companies have expressed strong support for the transaction.

Releasing the Definitive Proxy Statement

Avadel has initiated mailing its Definitive Proxy Statement to shareholders. This document not only provides comprehensive details about the merger but also serves as an instructional guide on how shareholders can participate in the decision-making process regarding the Scheme of arrangement.

Details on Upcoming Shareholder Meetings

Scheduled for January 12, 2026, the Scheme Meeting and the related Extraordinary General Meeting (EGM) will allow shareholders to discuss and vote on the merger. The company has highlighted the importance of these meetings, as they will outline the necessary actions for shareholders and provide insight into future company directions.

Avadel's Vision and Innovations

As part of its commitment to transforming lives, Avadel Pharmaceuticals has developed products like LUMRYZ™, which is recognized as the first and only once-at-bedtime oxybate for treating narcolepsy. The company’s innovative approach aims to address common challenges faced by patients, paving the way for better treatment options.

Commitment to Stakeholder Transparency

Avadel is dedicated to maintaining high levels of transparency as it progresses with the merger. This commitment includes providing shareholders with relevant information well in advance of meetings, ensuring they are prepared to make informed decisions.

Future Prospects for Avadel Pharmaceuticals

With the anticipated merger with Alkermes, Avadel looks forward to harnessing greater resources to support R&D and enhance its product portfolio. The potential synergies from this merger are expected to contribute significantly to the growth trajectory of the combined entity.

Frequently Asked Questions

What is the purpose of the Definitive Proxy Statement?

The Definitive Proxy Statement outlines the terms of the Proposed Transaction with Alkermes and includes important voting instructions for Avadel shareholders.

When are the Scheme Meeting and the EGM scheduled?

Both meetings are scheduled for January 12, 2026, allowing shareholders to vote on the merger with Alkermes.

What is LUMRYZ™?

LUMRYZ™ is Avadel's innovative medication that is the first once-at-bedtime oxybate approved for treating narcolepsy in adults and children aged seven and older.

How will the merger benefit Avadel shareholders?

The merger is expected to create synergies that enhance shareholder value through expanded resources and capabilities.

How can shareholders access the Definitive Proxy Statement?

Shareholders can access the Definitive Proxy Statement through Avadel's investor relations page and various filings made with the SEC.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Synova Global Taps Eventus for Top Trade Surveillance

Updated Category News Views 144

Synova and Eventus: A Powerful Partnership If you've ever traded a share or two, you know the name of the game is risk management. Step into Synova Global's latest move, and you'll see a gamble worth watching closely. This time around, Synova has tapped Eventus to bring their Validus trade surveillance platform into the fold. Now, Eventus and its star player, Validus,...

Continue Reading
Cambiotics Launches Key Trial on Reducing PFAS in Firefighters

Updated Category News Views 44

Pioneering Efforts to Combat 'Forever Chemicals' Cambiotics is stepping into some uncharted territory—tackling the tricky problem of PFAS accumulation in firefighters. If you’ve been following this, PFAS, or per- and polyfluoroalkyl substances, have been living rent-free in our bodies for years. Used in firefighting equipment and foams, these chemicals stick around,...

Continue Reading
ZBS Group Takes Over Rabinowitz’s CPA Practice with Bold Moves

Updated Category News Views 44

Transitioning Power in the CPA World Let's cut to the chase—when a seasoned CPA like Joseph Rabinowitz picks up the phone to secure a succession partner, it's a big deal. Enter ZBS Group LLP, steered by Michael Zaidman, which isn't a stranger to these waters, undertaking their fourth CPA practice acquisition through Rabinowitz's corner of the accounting universe....

Continue Reading
Connecting NIH Data: Transforming Scientific Discoveries

Updated Category News Views 44

Rethinking How Research Data Drives Discovery When researchers generate truckloads of data, finding patterns that lead to breakthroughs often becomes a game of hide and seek. It's like having a jumbo puzzle with pieces scattered all over the place. Enter the NIH Common Fund Data Ecosystem—a game changer attempting to glue together these pieces across the research...

Continue Reading
Cerbo's AI Scribe Expands to Telehealth Success

Updated Category News Views 46

Cerbo Enhances Telehealth With AI Scribe Expansion The digital healthcare playground looks like it's getting a nudge toward efficiency with Cerbo's latest move. Just when you thought telehealth couldn't get much sharper, these folks have drawn a line in the sand with their AI Scribe, which now makes its presence felt in virtual visits. No more juggling a dozen screens...

Continue Reading
SportsMed Expands to 58 Clinics, New Opening in Jersey City

Updated Category News Views 28

SportsMed Physical Therapy Expands with New Clinic Well, here we are, talking about expansion. And not just any expansion—I'm talking about SportsMed Physical Therapy flexing its muscles in Jersey City Heights, boosting their count to 58 clinics scattered across New Jersey and Connecticut. It's like watching a network of care roots spreading deeper into the region, and...

Continue Reading
Geopolitical Talks Shake Oil Market, Refine Stocks' Path

Updated Category News Views 92

Diplomacy Takes Center Stage So here we are again, riding the rollercoaster of geopolitics that's jerking the oil market around like a marionette. With the U.S. and Iran allegedly chatting—mind you, with a ton of smoke and mirrors through Qatar and Islamabad—every trader's watching, hoping for a ceasefire that might either stabilize or further jolt energy prices. Oil...

Continue Reading
Linker Vision's AI Platform Boosts Urban Planning

Updated Category News Views 72

Now, I've seen a fair share of tech rollouts claiming to change the world, but Linker Vision’s new AI platform, Linker AI Nexa, might actually be onto something real here. Revealed at the Smart City Expo World Congress 2026 in Barcelona, this isn't just another pretty interface—it’s packing some serious firepower with NVIDIA tech. Bringing Physical AI to City...

Continue Reading
Bright Minds Faces Legal Scrutiny Over FDA Trial Hold

Updated Category News Views 72

Bright Minds Biosciences Under the Microscope Well, it looks like Bright Minds Biosciences has found itself in some hot water with investors. After the FDA put a partial hold on their Phase 2 trial for BMB-101, designed for epilepsy treatment, the stock took a nosedive. If you're holding a piece of NASDAQ:DRUG, or even if you cut your losses and ran, it's time to tune in....

Continue Reading
Instanodes Tackling Quantum Threats in Blockchain

Updated Category News Views 114

Diving Into Quantum Cryptography for Blockchain Instanodes is throwing down the gauntlet for the blockchain crowd as the field of quantum computing edges ever closer to unsettling the cryptographic order. This company's latest play? Post-quantum account engineering for major players like Ethereum and Solana. And it's not just tinkering—they're giving the status quo a...

Continue Reading

Top 5 Most Recently Viewed Articles

IDX Composite Index Ends Lower Amid Mixed Stock Performance

Updated Category News Views 84

Market Overview In recent trading, Indonesian stocks exhibited a downward trend as the trading session concluded. The IDX Composite Index experienced a decline of 0.12%. This drop was primarily influenced by weaker performances across key sectors, including Infrastructure, Agriculture, and Basic Industry. Sector Performance By the end of the trading day in Jakarta,...

Continue Reading
Sensonics International's Study Highlights Taste Impairment in Weight Loss Drugs

Updated Category News Views 182

Impact of Weight Loss Medications on Taste Perception A groundbreaking study has recently emerged, unveiling critical sensory implications related to weight loss medications known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs). These medications, often prescribed for weight management, have raised new concerns regarding their impact on taste function. Conducted...

Continue Reading
FalconX Expands Services with Strategic 21shares Acquisition

Updated Category News Views 276

FalconX Expands Services with Strategic Acquisition The acquisition strengthens FalconX's market footprint, enhancing its offerings in trading and asset management. FalconX has officially completed its acquisition of 21shares, a prominent name in the realm of cryptocurrency exchange-traded products. This strategic move highlights FalconX's ambition to merge traditional...

Continue Reading
Tilly's Earnings Preview: What to Expect Ahead of the Report

Updated Category News Views 124

Understanding Tilly's Earnings Report Tilly's Inc (NYSE: TLYS) is gearing up for an important quarterly earnings report. Investors are eager to discover how the specialty retailer will perform financially. As they approach the date of the earnings presentation, many are contemplating what key metrics to watch for in the report. Projected Earnings Expectations Analyst...

Continue Reading
Celebrating the Legacy of Gerry Spence: A Legal Icon's Journey

Updated Category News Views 314

Remembering Gerry Spence: A Pioneer in Trial Law Gerry Spence, a monumental figure in the realm of trial law, has left an indelible mark on the legal landscape. As the founder of The Spence Law Firm, LLC, his death at the age of 96 filled the world with reflections on his remarkable legacy shaped over decades of fierce courtroom battles. Remarkable Career in the Courtroom...

Continue Reading